Case Report

Nephrectomy for Metastatic Kidney Tumor in Patients with Differentiated Thyroid Cancer: A Report of Two Cases

Haruhiko Yamazaki,1 Takeshi Kishida,2 Go Noguchi,2 Hiroyuki Iwasaki,1 Nobuyasu Suganuma,1 Katsuhiko Masudo,3 Hirotaka Nakayama,4 Toshinari Yamashita,1 Takashi Yamanaka,1 Yuko Sugawara,1 Yuka Matsubara,1 Kaori Kohagura,1 Yasushi Rino,4 and Munetaka Masuda4

1Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan
2Department of Urology, Kanagawa Cancer Center, Yokohama, Japan
3Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Yokohama, Japan
4Department of Surgery, Yokohama City University School of Medicine, Yokohama, Japan

Correspondence should be addressed to Haruhiko Yamazaki; h.yamazaki0413@kcch.jp

Received 2 July 2018; Accepted 25 October 2018; Published 11 November 2018

Academic Editor: Thomas Grünig

Copyright © 2018 Haruhiko Yamazaki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The occurrence of renal tumors originating from thyroid cancer is extremely rare with a prevalence of 0.47% [1]. Although radioactive iodine (RAI) therapy has been used to treat metastatic and recurrent differentiated thyroid cancer (DTC), no data establish the efficacy of RAI for the treatment of renal metastases. Thus, to date, effective treatment methods for renal metastasis from thyroid cancer remain unavailable. When a tumor is metastasized to the kidneys, it generally comprises other metastatic lesions or is bilateral [2]. Herein, we report cases of two patients with DTC who underwent nephrectomy for a metastatic kidney tumor.

1. Introduction

The occurrence of renal tumors originating from thyroid cancer is extremely rare with a prevalence of 0.47% [1]. Although radioactive iodine (RAI) therapy has been used to treat metastatic and recurrent differentiated thyroid cancer (DTC), no data establish the efficacy of RAI for the treatment of renal metastases. Thus, to date, effective treatment methods for renal metastasis from thyroid cancer remain unavailable. When a tumor is metastasized to the kidneys, it generally comprises other metastatic lesions or is bilateral [2]. Herein, we report cases of two patients with DTC who underwent nephrectomy for a metastatic kidney tumor.

2. Case Report

2.1. Case 1. A 74-year-old man was diagnosed with right kidney tumor on routine computed tomography (CT) 10 years after initial surgery. His medical history comprised near total thyroidectomy for papillary thyroid cancer (PTC) 10 years ago and complete thyroidectomy for recurrence 6 years ago. He did not complain of urinary symptoms such as flank pain or hematuria. Blood test results were as follows: creatinine (Cre), 0.78 mg/dL; blood urea nitrogen (BUN), 14.2 mg/dL; thyroid-stimulating hormone (TSH), 0.13 μIU/mL; free thyroxine (F-T4), 1.57 ng/mL; thyroglobulin (Tg), 95.0 ng/dL (Tg doubling time, 0.31 years); and Tg antibody (TgAb), 11 IU/mL. Transabdominal ultrasonography (US) revealed a right kidney tumor measuring 5.3 × 3.7 cm. The tumor blood flow was similar to that of the kidneys. In addition, CT revealed an irregular tumor mass projecting outward from the right kidney with no evidence of other metastatic lesions (Figure 1(a)). Despite a little marginally elevated Tg level, imaging studies of the right kidney raised suspicions of primary renal cell carcinoma (RCC). Following consultations
Figure 1: (a) Computed tomography showed the right kidney tumor (arrow). (b) The right nephrectomy specimen contained a grayish tumor measuring $5.5 \times 5.0$ cm on the upper pole (arrow). (c, d) Histologic sections of the resection specimen showed that the tumor formed a papillary structure, and the lumen was filled with eosinophilic substances considered colloids. Individual cancer cells had nuclear grooves, and findings suggestive of nuclear inclusions were also observed (arrow). (c): Original magnification x200, (d): Original magnification x400. (e, f) Immunohistochemistry revealed positive for thyroid transcription factor 1 (e) and thyroglobulin (f). Original magnification x400.
with urologists, a right laparoscopic radical nephrectomy was performed. The pathology report revealed that the right nephrectomy specimen contained a grayish tumor measuring $5.5 \times 5.0$ cm on the upper pole (Figure 1(b)). Histological sections of the resected specimen revealed that the tumor formed a papillary structure, and the lumen was filled with eosinophilic substances that were considered colloids. Further, individual cancer cells had nuclear grooves, and findings suggestive of nuclear inclusions were observed (Figures 1(c) and 1(d)). Immunohistochemistry (IHC) results were positive for thyroid transcription factor 1 (TTF-1) and Tg (Figures 1(e) and 1(f)). The patient was discharged from the hospital on postoperative day 7 without any complications. Postoperatively, the Tg level decreased to 3.05 ng/dL and, 3 years after nephrectomy, no recurrence has been reported.

2.2. Case 2. A 68-year-old woman, with medical history of total thyroidectomy for follicular thyroid carcinoma (FTC) 24 years ago, exhibited a high Tg level. However, she did not complain of any urinary symptoms. Her blood test results were as follows: Cre, 0.65 mg/dL; BUN, 14.7 mg/dL; TSH, 0.09 μIU/mL; F-T4, 1.35 ng/mL; Tg, 10500.0 ng/dL (Tg doubling time, 0.31 years); and TgAb, 11 IU/mL. CT revealed a left kidney tumor measuring 4.0 × 3.5 cm (Figure 2(a)). The Tg level was remarkably high; thus, recurrence of FTC was predominantly suspected. However, CT identified no other metastatic lesion, and nephrectomy was performed. The pathology report revealed that the left nephrectomy specimen comprised a light brown tumor measuring $4.5 \times 4.4$ cm on the lower pole (Figure 2(b)). In addition, histological sections of the resected specimen revealed that the tumor formed a follicular structure and was undergoing infiltration and proliferation (Figures 2(c) and 2(d)). Furthermore, IHC was positive for TTF-1 and Tg (Figures 2(e) and 2(f)). The patient was discharged from the hospital on postoperative day 6 without any complications. The Tg level decreased postoperatively to 298 ng/dL.

3. Discussion

In 2012, approximately 230,000 and 70,000 new cases of thyroid cancer were estimated among females and males, respectively, with an age-standardized (world population) rate of 6.10/100,000 females and 1.90/100,000 males [3]. Both PTC and FTC are called DTC, accounting for >95% of all thyroid carcinoma cases [4]. The prognosis of DTC is good, and the disease-specific survival rate is reportedly >90% [5]. However, some DTCs develop distant metastasis, the frequency of which has been reported to be 4 %-15 %, with the lung being the most frequent metastatic site [6]. The origin of renal tumor originating from thyroid cancer is extremely rare, with a prevalence of 0.47% [1]. Frequently, metastatic renal tumors exhibit poor clinical symptoms, and patients die before developing symptoms. Thus, it is rare for the cancer to be discovered during survival and be treated [7]. The duration from the diagnosis of thyroid cancer to the detection of renal metastasis is long, and cases >10 years have been reported previously [7, 8]. By the time renal metastasis was diagnosed in cases 1 and 2 of this report, 10 and 24 years had elapsed since initial surgery, respectively. In addition, both patients exhibited no subjective symptoms; however, kidney tumors were detected with whole body CT. The follow-up method following thyroid cancer surgery has recently changed from whole body RAI scanning to US and serum Tg [9]. In our cases, asymptomatic recurrent foci were detected by measuring the serum Tg level. Of note, whole body RAI scanning could also be used to detect recurrent foci after DTC surgery; however, a possibility of false positives exists for the kidneys because of other diseases, necessitating attention for evaluation [10, 11]. Although metastatic renal tumors require differentiation from primary RCC, CT and MRI do not have characteristic findings in metastatic renal tumor originating from thyroid cancer [7]. In our cases, a possibility of renal metastasis of thyroid cancer existed because the serum Tg level had increased. However, a case of thyroid cancer metastasized to RCC has been reported previously [12]. Whether the excision of distant metastasis contributes to the prognosis of thyroid cancer remains unclear. However, following consultation with urologists, we performed radical nephrectomy for diagnostic and therapeutic purposes in both cases. The efficacy of resection of distant metastases has been analyzed in various cancers. In colorectal cancer, hepatic resection is considered a standard treatment option for metastatic colorectal cancer and can result in 10-year survival rates of 20–26%, and potential cure. There is no established evidence in other cancers, but there are cases in which long-term prognosis is obtained by resection of oligometastasis [13]. Therefore, the resection of oligometastasis in thyroid cancer treatment might be considered a treatment option.

The pathology reports revealed characteristic features of DTC. A primary renal tumor that displays similar histology to FTC is known as thyroid-like follicular carcinoma of the kidney (TLFCK). TLFCK is an extremely rare histological variant of RCC; however, thyroid-specific immunohistochemical markers, such as TTF-1 and Tg, are negative [14]. In both cases, TTF-1 and Tg were positive by IHC, and it was feasible to diagnose renal metastasis of thyroid cancer.

RAI is used to treat DTCs that develop recurrence and distant metastasis. The prognosis of patients with the $^{131}$I uptake is better than those without the $^{131}$I uptake [15]. However, almost all studies reporting the efficacy of RAI comprised lung or bone metastasis cases, with no data demonstrating the efficacy of RAI for the treatment of renal metastases.

To date, radiiodine refractory DTC (RR-DTC) treatment options are very limited. However, sorafenib and lenvatinib, which are tyrosine kinase inhibitors (TKIs), have recently been approved and used to treat RR-DTCs [16, 17]. Although both drugs exhibit high efficacy, many patients are forced to discontinue because of adverse effects (AEs). In the DECISION trial, dose reductions were required in 64.3% of patients in the sorafenib group [16]. Similarly, in the SELECT trial, dose reductions were required in 67.8% of patients in the lenvatinib group and 90% of Japanese patients taking lenvatinib [17, 18]. Moreover, most patients in these trials had lung, lymph node, or bone metastasis, and the efficacy of TKI for renal metastasis remains unknown. In addition, AEs of TKI exhibit a possibility of substantially
Figure 2: (a) Computed tomography showed the left kidney tumor (arrow). (b) The left nephrectomy specimen contained a light brown tumor measuring 4.5 cm × 4.4 cm on the lower pole (arrow). (c, d) Histologic sections of the resection specimen showed that the tumor formed a follicular structure, and was infiltrating and proliferating. (c): Original magnification x200, (d): Original magnification x400. (e, f) Immunohistochemistry revealed positive for thyroid transcription factor 1 (e) and thyroglobulin (f). Original magnification x400.
decreasing patients’ quality of life. In our case, both patients were asymptomatic, and the efficacy of TKI was unknown for these disease conditions, thereby necessitating caution while introducing TKI. In contrast, surgery could result in definitive volume reduction. Overall, radical nephrectomy could be a reasonable treatment if there is no metastasis in other organs and it is not a case of bilateral kidney metastases [2, 7].

4. Conclusions

We reported cases of two patients with DTC who underwent nephrectomy with single metastasis to the kidneys. To date, the best treatment for renal metastasis of thyroid cancer remains debatable. However, this report suggests that nephrectomy for single renal metastasis could be considered a treatment option if patients’ general condition is positive. Nevertheless, long-term follow-up is necessary to assess efficacy.

Conflicts of Interest

The authors state that they have no conflicts of interest.

Acknowledgments

The authors thank enago (https://www.enago.jp/) for editing a draft of this manuscript.

References

[1] Z.-L. Qiu, Y.-L. Xue, and Q.-Y. Luo, “Rare renal metastases from differentiated thyroid carcinoma: Early clinical detection and treatment based on radioiodine,” *Arquivos Brasileiros de Endocrinologia & Metabologia*, vol. 58, no. 3, pp. 260–269, 2014.

[2] V. Nath, M. Baliga, J. Lewin, F. Souza, and I. Akhtar, “Follicular thyroid carcinoma metastatic to the kidney: report of a case with cytohistologic correlation,” *Case Reports in Pathology*, vol. 2015, Article ID 704143, 5 pages, 2015.

[3] C. La Vecchia, M. Malvezzi, C. Bosetti et al., “Thyroid cancer mortality and incidence: a global overview,” *International Journal of Cancer*, vol. 136, no. 9, pp. 2187–2195, 2015.

[4] B. Aschcroft-Kilfoy, M. H. Ward, M. M. Sabra, and S. S. Devesa, “Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006,” *Thyroid*, vol. 21, no. 2, pp. 125–134, 2011.

[5] K. Matsuzu, K. Sugino, K. Masudo et al., “Thyroid lobectomy for papillary thyroid cancer: Long-term follow-up study of 1,088 cases,” *World Journal of Surgery*, vol. 38, no. 1, pp. 68–79, 2014.

[6] C. A. Benbassat, S. Mechlis-Frish, and D. Hirsch, “Clinico-pathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer,” *World Journal of Surgery*, vol. 30, no. 6, pp. 1088–1095, 2006.

[7] Y. Inoue, H. Moriyama, H. Mochizuki, M. Nakahara, T. Nishizaka, and T. Fukuhara, “Metastatic renal tumor originating from thyroid cancer: a case report,” *Japanese Journal of Clinical Urology*, vol. 55, no. 11, pp. 1049–1051, 2001.

[8] K. Abe, T. Hasegawa, S. Onodera, Y. Oishi, and M. Suzuki, “Renal metastasis of thyroid carcinoma,” *International Journal of Urology*, vol. 9, no. 11, pp. 656–658, 2002.

[9] B. R. Haugen, E. K. Alexander, and K. C. Bible, “2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the american thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer,” *Thyroid*, vol. 26, no. 1, pp. 1–133, 2016.

[10] A. Claimon, M. Suh, G. J. Cheon, D. S. Lee, E. E. Kim, and J.-K. Chung, “Bilateral Renal Metastasis of Hurthle Cell Thyroid Cancer with Discordant Uptake Between I-131 Sodium Iodide and F-18 FDG,” *Nuclear Medicine and Molecular Imaging*, vol. 51, no. 3, pp. 256–260, 2017.

[11] Y.-X. Mi, X. Sui, J.-M. Huang, L.-G. Wei, and P. Xie, “Incidentally polycystic kidney disease identified by SPECT/CT with post-therapy radioiodine scintigraphy in a patient with differentiated thyroid carcinoma,” *Medicine*, vol. 96, no. 43, Article ID e8348, 2017.

[12] J. S. A. Song, S. M. Taylor, J. Trines et al., “Tumor-to-tumor metastases: Papillary thyroid carcinoma into a clear cell renal cell carcinoma,” *Journal of Otolaryngology - Head and Neck Surgery*, vol. 46, no. 1, article 17, 2017.

[13] D. K. Reyes and K. J. Pienta, “The biology and treatment of oligometastatic cancer,” *Oncotarget*, vol. 6, no. 11, pp. 8491–8524, 2015.

[14] M. Ghaoulit, L. Roquet, M. Baron, C. Pfister, and J.-C. Sabourin, “Thyroid-like follicular carcinoma of the kidney: a case report and review of the literature,” *Diagnostic Pathology*, vol. 9, article 186, 2014.

[15] C. Durante, N. Haddy, E. Baudin et al., “Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 91, no. 8, pp. 2892–2899, 2006.

[16] M. S. Brose, C. M. Nutting, and B. Jarzab, “Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial,” *The Lancet*, vol. 384, no. 9940, pp. 319–328, 2014.

[17] M. Schlumberger, M. Tahara, L. J. Wirth et al., “Lenvatinib versus placebo in radioiodine-refractory thyroid cancer,” *The New England Journal of Medicine*, vol. 372, no. 7, pp. 621–630, 2015.

[18] N. Kiyota, M. Schlumberger, K. Muro et al., “Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer,” *Cancer Science*, vol. 106, no. 12, pp. 1714–1721, 2015.